Generics

Politics Nicholas Florko

STAT Plus: Supreme Court deals a series of blows to generic drug companies

First Opinion Peter Kolchinsky

It’s time to bring generic drug manufacturing back to the U.S.

Pharmalot Ed Silverman

STAT Plus: Johnson & Johnson is fined $30 million for thwarting generics in France

First Opinion Dana P. Goldman and Tomas J. Philipson

Biosimilars competition helps patients more than generic competition

Pharmalot Ed Silverman

STAT Plus: Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks

Pharmalot Ed Silverman

STAT Plus: Washington may become the second state to distribute its own generic drugs

Pharmalot Ed Silverman

STAT Plus: To the delight of generic drug makers, federal appeals court tosses controversial ‘skinny labeling’ decision

Pharmalot Ed Silverman

STAT Plus: U.S. drug prices were more than double those in dozens of countries in 2018